Skip to main content

Cardlytics, Inc.

For the period ended Mar 31, 2025. Filed May 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

CDLX$1.63-10.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations (Unaudited)

(Amounts in thousands, except per share amounts)

Three Months EndedMarch 31,
20252024
Revenue$61,898$67,608
Costs and expenses:
Partner Share and other third-party costs29,45030,543
Delivery costs7,2886,173
Sales and marketing expense12,75414,118
Research and development expense11,70613,048
General and administrative expense13,77814,485
Change in contingent consideration605,817
Loss (gain) on disposal or divestiture(5,350)—
Depreciation and amortization expense6,2916,250
Total costs and expenses75,97790,434
Operating Loss(14,079)(22,826)
Other income (expense):
Interest expense, net(1,830)(819)
Foreign currency gain (loss)2,627(630)
Total other income (expense)797(1,449)
Loss before income taxes(13,282)(24,275)
Net Loss$(13,282)$(24,275)
Net Loss per share, basic and diluted$(0.26)$(0.56)
Weighted-average common shares outstanding, basic and diluted51,86343,248
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.